Clinical Trials Logo

Pregnancy clinical trials

View clinical trials related to Pregnancy.

Filter by:

NCT ID: NCT00967382 Completed - Pregnancy Clinical Trials

TIPPS: Thrombophilia in Pregnancy Prophylaxis Study

TIPPS
Start date: July 2000
Phase: Phase 3
Study type: Interventional

The TIPPS trial seeks to determine the safety and effectiveness of low-molecular-weight heparin (LMWH), an anticoagulant, in preventing placenta mediated pregnancy complications and venous thromboembolism (VTE) in women with thrombophilia. Thus, the principal research question is: can LMWH prevent thrombosis in the leg veins, pulmonary arteries and placental vessels, thereby reducing the risk of deep vein thrombosis, pulmonary embolism (PE), intrauterine growth restriction (IUGR), preeclampsia, miscarriage and stillbirth?

NCT ID: NCT00966771 Completed - Pregnancy Clinical Trials

The Copper T380A IUD vs. Oral Levonorgestrel for Emergency Contraception

IUD EC
Start date: October 2009
Phase: N/A
Study type: Observational

The purpose of this study is to see if women presenting for emergency contraception (EC) and choose the copper intrauterine device (IUD) will have fewer unplanned pregnancies in the next year compared to women who choose oral levonorgestrel for EC. The study will also compare use of an effective method of contraception in the year after they received EC.

NCT ID: NCT00957476 Completed - Obesity Clinical Trials

Omega-3 Supplementation Decreases Inflammation and Fetal Obesity in Pregnancy

Start date: September 2009
Phase: N/A
Study type: Interventional

Randomized, double-blind placebo controlled trial of fish oil to decrease inflammation in pregnancy.

NCT ID: NCT00950235 Completed - Obesity Clinical Trials

Weight Management for Improved Pregnancy Outcomes

Healthy Moms
Start date: October 2009
Phase: N/A
Study type: Interventional

This study will examine the safety and effectiveness of a dietary intervention in pregnant women. Women who are obese will be invited to participate. The control arm will receive routine prenatal care and one in-person nutritional and dietary counseling session to promote healthy eating during their pregnancy. The intervention arm will receive a more intensive dietary program that will include in-person counseling and group support sessions. The goal of the intervention will be weight maintenance (weight at 2 weeks after delivery should be within 3% of baseline weight) and avoidance of postpartum weight retention

NCT ID: NCT00942097 Completed - Pregnancy Clinical Trials

Homeopathic Medication and Nutritional Oriented Diet to Treat Overweight Pregnant Women With Mental Disorder

Start date: August 2009
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of homeopathic treatment in pregnant women with overweight and class I obesity with suspicion of a mental disorder.

NCT ID: NCT00938600 Completed - Pregnancy Clinical Trials

Antenatal Vitamin D3 Dose-finding and Safety Study

AViDD-1
Start date: July 2009
Phase: Phase 1
Study type: Interventional

This is a preliminary study of oral vitamin D3 supplementation in pregnant and non-pregnant women of reproductive age in Bangladesh. The primary objective of the study is to identify a dose of vitamin D3 that can safely be administered during pregnancy to improve the vitamin D status of the mother and infant.

NCT ID: NCT00928538 Completed - Pregnancy Clinical Trials

Nurse Family Partnership (NFP) Contraceptive Study

NFP2
Start date: September 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether nurses can help at-risk women reduce the incidence of unintended pregnancy by providing them access to hormonal contraceptives in their homes.

NCT ID: NCT00912132 Completed - Pregnancy Clinical Trials

The National Standard for Normal Fetal Growth

Start date: May 19, 2009
Phase:
Study type: Observational

Normal fetal growth is a critical component of a healthy pregnancy and the long-term health of the offspring. Pivotal to understanding the dynamics of human fetal growth and to defining normal and abnormal fetal growth is the development of standards for fetal growth. The study's purpose was to establish standards for normal fetal growth and size for gestational age for 4 racial/ethnic groups of pregnant women with the eventual creation of individualized standards for fetal growth and improvements in fetal weight estimation. These data for a contemporary cohort of pregnant women should provide data for clinical management.

NCT ID: NCT00894257 Completed - HIV Infections Clinical Trials

Trends in Risk Factors for Mother-to-Child Transmission of Hepatitis C Among a Southern European Population

EPIALHICE B
Start date: May 25, 2009
Phase:
Study type: Observational

According to the centres taking part in the ALHICE survey, the number of HIV-HCV co-infected women is currently decreasing. This drop was first noted in 2006 and persisted in 2007. What might have been considered a chance phenomenon during the first year (2006) was confirmed in the beginning of 2008. In view of this information, the investigators wished to ascertain the reality of this trend and to investigate its causes, by attempting to answer the following questions: - Has the prevalence of risk factors for HCV infection changed among the general population over the past 10 years? - Has the prevalence of risk factors for HCV infection changed among HIV/HCV co-infected women over the past 10 years? - Is the change in the number of co-infected women who gave birth during the past 10 years related to the prevalence of certain risk factors among this population? - Is the change in the number of co-infected women who gave birth during the past 10 years related to a decrease in certain risk factors for HCV infection among the general population? - Have changes in addictive behaviour among women of child-bearing age played a role in the decreasing number of HCV-contaminated children? Furthermore, follow-up data from HCV-infected children born during this period will provide information concerning the course of HCV infection. The objectives are to study trends in numbers of deliveries among HCV/HIV co-infected women as well as trends in risk factors for HCV infection among women of child bearing age and lastly to create a cohort of HCV infected children.

NCT ID: NCT00882648 Completed - Pregnancy Clinical Trials

The Effect of Fetal Gender on Maternal Substance Abuse Treatment

Start date: April 2009
Phase: N/A
Study type: Observational

Previous studies by this team of investigators has determined that male infants are more likely to display more severe neonatal abstinence syndrome (NAS) as a result of maternal opioid use during pregnancy (Jansson, 2007)and there is appears to be a gender-related biologic vulnerability to NAS expression (Jansson, 2009, submitted). The proposed study explores the relationship between fetal gender and substance abuse treatment outcomes among a population of women in comprehensive substance abuse treatment to explore the possibility of a psychosocial vulnerability among drug exposed male fetuses as opposed to female fetuses. Women in substance abuse treatment are a group at high risk for current exposure to violence, usually at the hands of significant others, and having a history of sexual abuse as a child, usually resulting from contact with a male family member. Therefore, they often have difficult relationships with men. At the Center for Addiction and Pregnancy (CAP), a 2006 study revealed that among a group of 715 pregnant women, reports of the exposure to violence was very high. Their rates of lifetime abuse ranged from 72.7% for physical abuse to 44.5% for sexual abuse. Rates of abuse remained high during their current pregnancy, ranging from 20% for physical abuse to 7.1% for sexual abuse (Velez, 2006). The abuse was very often at the hands of partners or other male family member perpetrators. We hypothesize that women carrying male fetuses will be less likely to remain complaint in drug treatment or abstinent from illicit drug use, while women carrying female fetuses may be more likely to remain drug abstinent and treatment compliant. If supported, this theory has the potential to inform fetal gender specific treatment for pregnant drug dependent women. Additionally, we seek to support the previously documented link between male gender and more severe expression of NAS, and explore the relationship between other maternal prescribed drug use (i.e. psychotropic medications) and severity of NAS expression.